The present invention relates to pharmaceutical compositions comprising a first component comprising dabigatran or a pharmaceutically acceptable salt thereof in the form of a tablet and a second component comprising an organic acid. The invention also relates to processes for the preparation of such compositions and using those compositions to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
